[go: up one dir, main page]

MX2025002929A - Compuestos de objetivo brm y metodos de uso asociados - Google Patents

Compuestos de objetivo brm y metodos de uso asociados

Info

Publication number
MX2025002929A
MX2025002929A MX2025002929A MX2025002929A MX2025002929A MX 2025002929 A MX2025002929 A MX 2025002929A MX 2025002929 A MX2025002929 A MX 2025002929A MX 2025002929 A MX2025002929 A MX 2025002929A MX 2025002929 A MX2025002929 A MX 2025002929A
Authority
MX
Mexico
Prior art keywords
associated methods
targeting compounds
brm
compounds
brm targeting
Prior art date
Application number
MX2025002929A
Other languages
English (en)
Inventor
Corey Howard Basch
Song Mei
Liang Liu
Artem Shvartsbart
Andrew Combs
John A Rose
Sina Rezazadeh
Danielle Beam Roth
Klare L Bersch
Vijayarajan Devannah
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2025002929A publication Critical patent/MX2025002929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a compuestos de Fórmula (I) (ver formula) También se describen composiciones farmacéuticas comprendiendo compuestos de Fórmula (I), así como métodos para su uso y preparación.
MX2025002929A 2022-09-15 2025-03-12 Compuestos de objetivo brm y metodos de uso asociados MX2025002929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263375739P 2022-09-15 2022-09-15
PCT/US2023/074324 WO2024059806A1 (en) 2022-09-15 2023-09-15 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
MX2025002929A true MX2025002929A (es) 2025-05-02

Family

ID=88600168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025002929A MX2025002929A (es) 2022-09-15 2025-03-12 Compuestos de objetivo brm y metodos de uso asociados

Country Status (10)

Country Link
US (1) US20240165244A1 (es)
EP (1) EP4587127A1 (es)
JP (1) JP2025532611A (es)
KR (1) KR20250065894A (es)
CN (1) CN120282966A (es)
AU (1) AU2023342153A1 (es)
CA (1) CA3267479A1 (es)
IL (1) IL319545A (es)
MX (1) MX2025002929A (es)
WO (1) WO2024059806A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
WO2025194059A1 (en) 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4240743A1 (en) * 2020-11-06 2023-09-13 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
US20240165244A1 (en) 2024-05-23
CN120282966A (zh) 2025-07-08
CA3267479A1 (en) 2024-03-21
JP2025532611A (ja) 2025-10-01
WO2024059806A1 (en) 2024-03-21
AU2023342153A1 (en) 2025-04-10
IL319545A (en) 2025-05-01
KR20250065894A (ko) 2025-05-13
EP4587127A1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
MX2025002929A (es) Compuestos de objetivo brm y metodos de uso asociados
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
EP4609865A3 (en) Nlrp3 inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
CR20230413A (es) Moduladores de sting (estimulador de genes de interferón)
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
AU2020231934A8 (en) Compounds useful in HIV therapy
PH12022553420A1 (en) Amidopyrimidone derivatives
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2025005972A (es) Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3)
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MX2023002525A (es) Nuevos compuestos.
MX2023012204A (es) Derivados de piperidina urea como inhibidores de la epóxido hidrolasa soluble.
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals